2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13873
    IKK-IN-1 406211-06-1
    IKK-IN-1 is an inhibitor of IKK extracted from patent WO2002024679A1, compound example 18-13.
    IKK-IN-1
  • HY-14296
    PF-610355 862541-45-5 98%
    PF-610355 is a long-acting inhaled β2-adrenoreceptor agonist, with an EC50 of 0.26 nM. PF-610355 has the potential for the study of asthma and COPD.
    PF-610355
  • HY-14390
    LAS101057 925676-48-8 99.92%
    LAS101057 is a potent, selective, and orally efficacious A2B receptor antagonist.
    LAS101057
  • HY-14743
    Golotimod 229305-39-9 98.04%
    Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
    Golotimod
  • HY-14900
    Tedalinab 916591-01-0 99.84%
    Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.
    Tedalinab
  • HY-14939
    Vapitadine 793655-64-8 99.77%
    Vapitadine is a non-sedative antihistamine compound that alleviates itching associated with atopic dermatitis.
    Vapitadine
  • HY-15035
    S-Diclofenac 912758-00-0 99.20%
    S-Diclofenac (ACS 15) is a hybrid molecule of an H2S donor and the NSAID diclofenac. S-Diclofenac activates the p53 signaling pathway, and inhibits the activation of JNK. S-Diclofenac exhibits antioxidant and anti-inflammatory activities.
    S-Diclofenac
  • HY-15105
    SB-423562 351490-27-2 99.66%
    SB-423562 is a short-acting calcium-sensing receptor (CaR) antagonist. SB-423562 has the potential for osteoporosis research.
    SB-423562
  • HY-15131
    PNRI-299 550368-41-7 98%
    PNRI-299 is a selective AP-1 transcription inhibitor with an IC50 of 20 uM. PNRI-299 is a selective APE/Ref-1 inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM). PNRI-299 significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model.
    PNRI-299
  • HY-15784
    NPPM 6748-481 432020-20-7 99.60%
    NPPM 6748-481 is a potent and selective yeast Sec14 inhibitor with a yeast Sec14 IC50 of 211 nM. NPPM 6748-481 disrupts membrane trafficking, impairing trans-Golgi network-endosomal transport and endocytic transport. NPPM 6748-481 impairs Snc1 v-SNARE recycling, secretory invertase trafficking, and vacuolar carboxypeptidase Y processing. NPPM 6748-481 can be used for research on yeast infection.
    NPPM 6748-481
  • HY-16344
    Nedocromil sodium 69049-74-7 98%
    Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
    Nedocromil sodium
  • HY-16707
    CH 5450 252557-97-4 98.19%
    CH 5450 (Z-Ile-Glu-Pro-Phe-Ome) is a selective short peptide human cardiac chymase inhibitor. CH-5450 inhibits the action of rat MAB elastase 2 on substrate Ang I with an IC50 value of 49 µM and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide with an IC50 value of 4.8 µM.
    CH 5450
  • HY-17477
    Guacetisal 55482-89-8 98.87%
    Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.
    Guacetisal
  • HY-17488
    Morniflumate 65847-85-0 98%
    Morniflumate (UP 164) is an orally active nonsteroidal anti-inflammatory agent. Morniflumate can be used in the study of inflammatory diseases such as osteoarthritis, painful musculoskeletal disorders and soft tissue inflammation.
    Morniflumate
  • HY-18164
    TASP0277308 945725-50-8 99.00%
    TASP0277308 is a highly selective S1P1 antagonist. TASP0277308 possesses immunomodulatory activities, including lymphopenia, a block in T cell egress from the thymus, marginal zone B cell displacement, and the upregulation of CD69 expression on lymphocytes. TASP0277308 can be used for the research of collagen-induced arthritis in mice.
    TASP0277308
  • HY-18551
    DAGLβ-IN-1 1402612-61-6 98.22%
    DAGLβ-IN-1 is an inhibitor of diacylglycerol lipase-β (DAGLβ), serves as a versatile intermediate for the design of DAGL-tailored activity-based probes.
    DAGLβ-IN-1
  • HY-18710
    BMS-066 914946-88-6 99.09%
    BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively.
    BMS-066
  • HY-18734
    Carboxy-PTIO 145757-47-7 98%
    Carboxy-PTIO is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.
    Carboxy-PTIO
  • HY-18745
    BzATP triethylammonium 112898-15-4 98%
    BzATP triethylammonium acts as a P2X receptor agonist with pEC50s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively. BzATP triethylammonium is potent at P2X7 receptors with EC50s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively.
    BzATP triethylammonium
  • HY-18787
    c-Fms-IN-2 791587-67-2 99.79%
    c-Fms-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM.
    c-Fms-IN-2
Cat. No. Product Name / Synonyms Application Reactivity